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Posterior reversible encephalopathy syndrome (PRES) is a clinicoradiologic entity characterized by headaches,
altered mental status, seizures, and visual disturbances. It can occur in many different clinical entities such as severe
hypertension and pre-eclampsia, or due to cytotoxic or immunosuppressive therapies. The pathogenesis of PRES is
unclear, with dysregulated cerebral auto-regulation and endothelial dysfunction as important mechanisms proposed.
Endothelial dysfunction is important especially in cases associated with cytotoxic therapies. Herein, we describe a
patient with PRES with fatal outcome, who presented 5 days after the infusion of cycle 1 of irinotecan hydrochloride,
leucovorin calcium, and fluorouracil (FOLFIRI) regimen chemotherapy, without prior hypertension and other
comorbidity, suggesting a link between PRES and FOLFIRI regimen. To our knowledge, this case report is the
first describing PRES after FOLFIRI regimen, although others have described PRES after FOLFIRI with bevacizumab
in colonic cancer patients.
Keywords: Chemotherapy, Fluoropyrimidine, Fluorouracil, Irinotecan, Posterior reversible encephalopathy
syndromeBackground
Posterior reversible encephalopathy syndrome (PRES),
or reversible posterior leukoencephalopathy syndrome
(RPLS), is a clinicoradiologic entity characterized by
headaches, altered mental status, seizures, and visual dis-
turbances. It is associated with white matter vasogenic
oedema predominately affecting the posterior occipital
and parietal lobes of the brain [1].
It can occur in many different clinical entities such as
severe hypertension and pre-eclampsia, or due to cyto-
toxic or immunosuppressive therapies, but all these het-
erogeneous aetiologies are grouped together because of
similar neuroimaging findings. It is also often referred to
as reversible posterior cerebral oedema syndrome, or hy-
perperfusion encephalopathy, or brain capillary leak syn-
drome. Nevertheless, none of these names is completely* Correspondence: natalija.dedic-plavetic@zg.t-com.hr
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article, unless otherwise stated.satisfactory; the syndrome is not always reversible, and it
is often not confined to either the white matter or the
posterior regions of the brain. The pattern of oedema in
PRES can be widespread and can involve the entire
brain. It was first described in 1996, when Hinchey et al.
originally described a posterior hypertensive encephalop-
athy syndrome with a predominant posterior distribu-
tion of imaging findings on computed tomography (CT)
or magnetic resonance imaging (MRI) [2].
PRES is often unsuspected by clinicians, and therefore
a radiologist’s recognition of the characteristic imaging
findings is key in diagnosing this syndrome. It not only
helps in not delaying therapeutic measures, but also in
preventing deleterious work-ups or wrong therapeutic
approaches [3].
The pathogenesis of PRES is unclear, but the most pro-
minent feature is dysregulated cerebral autoregulation and
endothelial dysfunction [4]. Endothelial dysfunction is an
important mechanism in the pathophysiology of PRES, es-
pecially in cases associated with cytotoxic therapies orCentral Ltd. This is an Open Access article distributed under the terms of the
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versial. One theory postulates injury to capillary bed sec-
ondary to hypertension, leading to hyperperfusion and
cerebral oedema. However, the theory fails to explain both
the absence of underlying hypertension in up to 20 to 30%
of patients and the lack of a positive correlation between
cerebral oedema and severity of hypertension. Another
hypothesis is that vasoconstriction in response to evolving
hypertension leads to reduced brain perfusion and cere-
bral oedema [5,6]. Cytotoxic drugs have direct toxic effects
on vascular endothelial cells, leading to disrupted blood-
brain barrier, consequent capillary leakage, and vasogenic
oedema.
Common neuroradiological findings include scattered
hypodense regions involving bilateral cerebral hemispheres
on multislice computed tomography (MSCT) scans in up
to half of the cases. Differential diagnosis includes many
conditions such as stroke, vasculitis, encephalitis, venous
thrombosis, toxic or metabolic encephalopathy, and de-
myelinating disorders, among others.
Fatal outcome may result from increased intracranial
pressure, mostly due to progressive cerebral oedema,
intracerebral haemorrhage, or as a complication of the
underlying conditions. However, one of the largest case
series reported highlights the potential grave conse-
quences of this disorder; among 22 patients studied, 6
died and many survivors had permanent neurologic dis-
ability [7].
Herein, we describe the case of a patient with PRES
who presented 5 days after the infusion of cycle 1 of iri-
notecan hydrochloride, leucovorin calcium, and fluoro-
uracil (FOLFIRI) regimen chemotherapy, suggesting a
link between PRES and FOLFIRI regimen.
Case presentation
A 45-year-old woman diagnosed with stage IV metastatic
colorectal cancer one month previous, was admitted to
hospital due loss of consciousness after a grand mal seiz-
ure attack; she had had no previous seizures. Medical his-
tory revealed conisation due to cervical intraepithelial
neoplasia CIN III at the age of 26, with regular gynaecolo-
gic follow-up visits afterwards. Familiar history revealed
the mother diagnosed with endometrial cancer, father had
died due to colonic carcinoma, and grandfather had died
due to urinary bladder carcinoma. At the age of 45 she
presented with an acute abdomen and underwent urgent
surgery due to perforated carcinoma of the sigmoid colon.
A Hartmann operation was performed and several hepatic
metastases were found as well as an osteolytic lesion of
the right acetabulum which was conformally irradiated be-
fore starting chemotherapy. Palliative irradiation with a
total dose of 20 Gy on the right hip was performed. Five
days before admission, cycle 1 of FOLFIRI chemothera-
peutic regimen was started. The patient’s performancestatus before chemotherapy was excellent and without
any signs of infection and/or sepsis. Dosing consisted
of irinotecan, 180 mg/m2; leucovorin, 400 mg/m2 (both in
2 hours infusion); fluorouracil, 400 mg/m2 (intravenous
push) on Day 1 of cycle 1; and fluorouracil, 2,400 mg/m2
(48 hours infusion) during Day 1 and Day 2.
On Day 5 after FOLFIRI administration the patient
awoke with a headache and after a few minutes experi-
enced two episodes of generalized tonic-clonic seizures
and was urgently admitted to hospital. She had no focal
neurologic deficit. The patient’s blood pressure during
hospitalization was mildly elevated (systolic blood pres-
sure range 140 to 150 mm Hg, diastolic 100 to 105).
MSCT contrast enhanced scan was performed on ad-
mission and revealed hypodense areas in subcortical white
matter parasagitally in parieto-occipital region bilaterally.
Identical, but more discrete changes were found bilaterally
in the frontal region. There were no metastatic lesions,
hydrocephalus, or intracranial haemorrhage. MSCT fin-
ding was suspicious of PRES and MRI of the brain was
performed with Siemens Magnetom Symphony (Siemens,
Erlangen, Germany). Contrast media was injected intra-
venously. MRI revealed patchy areas of increased fluid
attenuated inversion recovery signal intensity in the oc-
cipital and posterior parietal lobes, consistent with RPLS
(Figure 1).
After two days of intensive therapy consisting of grad-
ual blood pressure control and anti-oedematous therapy
with 100 mL of 20% mannitol intravenously four times
daily, and levetiracetam 500 mg intravenously twice a
day, the patient fell into a coma and died a few hours
later. Autopsy revealed lung and liver metastases, and
prominent cerebral oedema with enlarged perivascular
and pericellular spaces. There was focal subarachnoidal
haemorrhage in the left frontoparietal region, without
blood penetration into cerebral parenchyma. There was
no cerebral infection on autopsy specimens. Other pos-
sible causes, such as progressive multifocal leukoence-
phalopathy, were also considered but ruled out clinically
and radiologically.
Conclusions
To our knowledge, this case report is the first describing
PRES after FOLFIRI regimen, although others have de-
scribed PRES after FOLFIRI with bevacizumab in co-
lonic cancer patients [8-10] and breast cancer patients
[11]. It is not surprising that bevacizumab is related with
PRES due to its mechanism of action and vasculature
being involved in pathogenesis. Our patient experienced
fatal outcome PRES after only one cycle of FOLFIRI che-
motherapy regimen, and without prior hypertension and
other comorbidity. A relative paucity of sympathetic ad-
renergic innervation to the vertebral basilar system is
suggested to account for the tendency for this syndrome
Figure 1 MRI brain images, axial and coronal. (A and B) Axial FLAIR images show bilateral cortical/subcortical hyperintense lesions involving
occipital lobes and frontal and parietal watershed zines-typical findings in PRES. (C) Coronal T2W image demonstrating predilection of PRES for
posterior circulation-bilateral, almost symmetric areas of oedema in parietal and occipital lobes and cerebellar hemispheres.
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lation [12]. There were no other predisposing factors
consistent with this proposed mechanism of vascular dy-
sregulation such as those described by Tam et al. [13],
who regard patients with significant fluid overload (more
than 10% of the baseline weight), a mean blood pressure
higher than 25% of baseline, and a creatinine level grea-
ter than 1.8 mg/dL (160 μmol/L) to be high risk for RPLS.
Although our patient had a mean blood pressure higher
than 25% of baseline, she was not otherwise at high risk
for the development of PRES. She was not hypervole-
mic and her serum creatinine level was normal. Former
palliative radiotherapy of right acetabulum with only
20 Gy total dose was not likely to cause clinically relevant
immune-compromised status. Therefore, we did not find
it as a significant possible cause of PRES in our patient.
Despite sigmoid colon perforation, there were no sepsis
and abdominal infection which might predispose the pa-
tient to PRES. Direct causal relationships between chemo-
therapy agents and PRES have been difficult to establish,
and the correlation is more common with cyclosporine
and tacrolimus. Other associated agents include metho-
trexate, the alpha interferons, cisplatin, cytarabine, cyclo-
phosphamide, doxorubicin hydrochloride (Adriamycin),
vincristine sulfate (Oncovin), and prednisone, or combina-
tions involving doxorubicin, ifosfamide, and etoposide.
The pathophysiology linking fluoropyrimidines like
fluorouracil has not been well described, but several pa-
thogenic explanations have been suggested. The role
of fluoropyrimidines and oxaliplatin in PRES has been
described in Femia’s et al. case report and literature
review [14].The cerebral toxicity of fluorouracil, although rare, is
well described as a multifocal inflammatory leukoence-
phalopathy [15,16]. Multifocal inflammatory leukoence-
phalopathy typically develops from 6 weeks to 5 months
after the initiation of combination chemotherapy with
levamisole hydrochloride and fluorouracil. Encephal-
opathy in our patient developed only five days after
chemotherapy administration. Multifocal inflammatory
leukoencephalopathy is a clinically and radiographically
distinct syndrome from PRES. To our knowledge, no re-
ports in the literature associate irinotecan, a type I topo-
isomerase inhibitor, with the development of PRES or
other encephalopathy syndromes. Leucovorin, a derivative
of folic acid, would not be expected to contribute to the
development of PRES. Several other investigators ob-
served an association between PRES and bevacizumab
administration [10,17]. Toxic damage to the vascular en-
dothelium or blood-brain barrier caused by immunosup-
pressant and cytotoxic medications is further postulated
to contribute to the pathophysiological features of PRES
[18]. In this case, we could point to either of the cytotoxic
agents fluorouracil or irinotecan. CT may show scattered
hypodense regions involving bilateral cerebral hemis-
pheres in up to half of the cases [19,20]. In our patient,
hypodense areas in subcortical white matter parasagitally
in parieto-occipital region bilaterally were found on CT
imaging.
Furthermore, haemorrhage is increasingly being recog-
nised in PRES and does not exclude the diagnosis [21].
This can be anatomically located in the brain paren-
chyma as a focal haematoma or petechial gyral pattern,
or in the subarachnoid space. Intracranial haemorrhage
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mately 15%, range 10 to 17% in different studies [22].
The pathological mechanism is still not well understood
but is thought to relate to hypertension and hyperper-
fusion or vasculopathy with resulting hypoperfusion.
Varying patterns of haemorrhage have been identified,
including large focal haematomas, subarachnoid haem-
orrhage (like in our patient), or multiple minute foci of
haemorrhage [23].
Prompt recognition of this syndrome will allow initi-
ation of immediate treatment and appropriate alterations
in chemotherapy regimens. Clinical suspicion with abrupt
onset of symptoms in certain subsets of susceptible pa-
tients and imaging, especially MRI, plays an essential role
in diagnosing this condition that radiologists and clini-
cians should be well aware of.
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